Description_x000D_ Packaging_x000D_ 5, 25 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ CFTR mutations are responsible for cystic fibrosis. The most common mutation is ΔF508, but many others exist. Drugs which can correct channel function of a broad range of CFTR mutants are most desirable for clinical development. PG-01 is a potentiator of ΔF508 (Ka 70 nM) as well as mutants G551D and G1349D (Ka 1100 and 40 nM, respectively). Its broad spectrum may make it more desirable than more mutant-specific CFTR correctors._x000D_ Features and Benefits_x000D_ This compound is featured on the Chloride Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.